Molecular determinants and feedback circuits regulating type 2 CRH receptor signal integration

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 5, 2011, Pages 896-907

  Markovic, Danijela ^a   Punn, Anu ^a   Lehnert, Hendrik ^a   Grammatopoulos, Dimitris K ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

arrestin1; AKAP; CRH receptor; ERK1 2; PKA; Ucn2

Indexed keywords

BETA ARRESTIN 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2BETA; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE C; UNCLASSIFIED DRUG; UROCORTIN II;

ARTICLE; CELL MEMBRANE; CELL STRAIN HEK293; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; INTERNALIZATION; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

A KINASE ANCHOR PROTEINS; ARRESTINS; CELL MEMBRANE; CHROMONES; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENDOCYTOSIS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEEDBACK, PHYSIOLOGICAL; HEK293 CELLS; HUMANS; MODELS, BIOLOGICAL; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SIGNAL TRANSDUCTION; UROCORTINS;

EID: 79955665184     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.02.005     Document Type: Article

References (50)

1. Hillhouse E.W., Grammatopoulos D.K. The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr. Rev. 2006, 27:260-286.
2. Kuperman Y., Chen A. Urocortins: emerging metabolic and energy homeostasis perspectives. Trends Endocrinol. Metab. 2008, 19:122-129.
3. Chen A., Brar B., Choi C.S., Rousso D., Vaughan J., Kuperman Y., Kim S.N., Donaldson C., Smith S.M., Jamieson P., Li C., Nagy T.R., Shulman G.I., Lee K.F., Vale W. Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc. Natl Acad. Sci. USA 2006, 103:16580-16585.
4. Bale T.L., Contarino A., Smith G.W., Chan R., Gold L.H., Sawchenko P.E., Koob G.F., Vale W.W., Lee K.F. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat. Genet. 2000, 24:410-414.
5. Coste S.C., Quintos R.F., Stenzel-Poore M.P. Corticotropin-releasing hormone-related peptides and receptors: emergent regulators of cardiovascular adaptations to stress. Trends Cardiovasc. Med. 2002, 12:176-182.
6. Bale T.L., Giordano F.J., Vale W.W. A new role for corticotropin-releasing factor receptor-2: suppression of vascularization. Trends Cardiovasc. Med. 2003, 13:68-71.
7. Taché Y., Bonaz B. Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J. Clin. Invest. 2007, 117:33-40.
8. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., Hogenesch J.B., Gulyas J., Rivier J., Vale W.W., Sawchenko P.E. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl Acad. Sci. USA 2001, 98:2843-2848.
9. Ladds G., Davis K., Hillhouse E.W., Davey J. Modified yeast cells to investigate the coupling of G protein-coupled receptors to specific G proteins. Mol. Microbiol. 2003, 47:781-792.
10. Kageyama K., Furukawa K., Miki I., Terui K., Motomura S., Suda Vasodilative T. Effects of urocortin II via protein kinase A and a mitogen-activated protein kinase in rat thoracic aorta. J. Cardiovasc. Pharmacol. 2003, 42:561-565.
11. Brar B.K., Jonassen A.K., Egorina E.M., Chen A., Negro A., Perrin M.H., Mjøs O.D., Latchman D.S., Lee K.F., Vale W. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 2004, 145:24-35.
12. Kageyama K., Suda T. Urocortin-related peptides increase interleukin-6 output via cyclic adenosine 5'-monophosphate-dependent pathways in A7r5 aortic smooth muscle cells. Endocrinology 2003, 144:2234-2241.
13. Sananbenesi F., Fischer A., Schrick C., Spiess J., Radulovic J. Mitogen-activated protein kinase signaling in the hippocampus and its modulation by corticotropin-releasing factor receptor 2: a possible link between stress and fear memory. J. Neurosci. 2003, 23:11436-11443.
14. Grammatopoulos D., Randeva H., Levine M.A., Katsanou E., Hillhouse E.W. Urocortin but not corticotropin-releasing hormone (CRH) activates the MAP kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1 and R2β CRH receptor subtypes and stimulation of Gq-proteins. Mol. Endocrinol. 2000, 14:2076-2091.
15. Brar B.K., Chen A., Perrin M.H., Vale W. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1α and 2β by the CRF/urocortin family of peptides. Endocrinology 2004, 145:1718-1729.
16. Rossant C.J., Pinnock R.D., Hughes J., Hall M.D., McNulty S. Corticotropin-releasing factor type 1 and type 2alpha receptors regulate phosphorylation of calcium/cyclic adenosine 3', 5'-monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase. Endocrinology 1999, 140:1525-1536.
17. Markovic D., Punn A., Lehnert H., Grammatopoulos Intracellular D.K. mechanisms regulating corticotropin-releasing hormone receptor-2βeta endocytosis and interaction with extracellularly regulated kinase 1/2 and p38 mitogen-activated protein kinase signaling cascades. Mol. Endocrinol. 2008, 22:689-706.
18. Punn A., Levine M.A., Grammatopoulos D.K. Identification of signaling molecules mediating CRH-R1α-MAPK interactions: the critical role of PI3-K in regulating ERK1/2 but not p38 MAPK activation. Mol. Endocrinol. 2006, 20:3179-3195.
19. Dumaz N., Marais R. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signaling pathways. FEBS Lett. 2005, 272:3491-3504.
20. Daaka Y., Luttrell L.M., Lefkowitz R.J. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997, 390:88-91.
21. Papadopoulou N., Chen J., Randeva H.S., Levine M.A., Hillhouse E.W., Grammatopoulos D.K. Protein kinase A-induced negative regulation of the corticotropin-releasing hormone R1alpha receptor-extracellularly regulated kinase signal transduction pathway: the critical role of Ser301 for signaling switch and selectivity. Mol. Endocrinol. 2004, 18:624-639.
22. Kilianova Z., Basora N., Kilian P., Payet M.D., Gallo-Payet N. Human melanocortin receptor 2 expression and functionality: effects of protein kinase A and protein kinase C on desensitization and internalization. Endocrinology 2006, 147:2325-2337.
23. Mundell S.J., Pula G., More J.C., Jane D.E., Roberts P.J., Kelly E. Activation of cyclic AMP-dependent protein kinase inhibits the desensitization and internalization of metabotropic glutamate receptors 1a and 1b. Mol. Pharmacol. 2004, 65:1507-1516.
24. Tao J., Malborn C.C. G-protein-coupled receptor-associated A-kinase anchoring proteins AKAP5 and AKAP12: differential signaling to MAPK and GPCR recycling. J. Mol. Signal. 2008, 3:19.
25. Lin F.T., Miller W.E., Luttrell L.M., Lefkowitz R.J. Feedback regulation of beta-arrestin1 function by extracellular signal-regulated kinases. J. Biol. Chem. 1999, 274:15971-15974.
26. Pitcher J.A., Tesmer J.J., Freeman J.L., Capel W.D., Stone W.C., Lefkowitz R.J. Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by extracellular signal-regulated kinases. J. Biol. Chem. 1999, 274:34531-34534.
27. Van Kolen K., Dautzenberg F.M., Verstraeten K., Royaux I., De Hoogt R., Gutknecht E., Peeters P.J. Corticotropin releasing factor-induced ERK phosphorylation in AtT20 cells occurs via a cAMP-dependent mechanism requiring EPAC2. Neuropharmacology 2010, 58:135-144.
28. Traver S., Marien M., Martin E., Hirsch E.C., Michel P.P. The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMP-dependent signaling pathway. Mol. Pharmacol. 2006, 70:30-40.
29. Calderón-Sanchez E., Delgado C., Ruiz-Hurtado G., Domínguez-Rodríguez A., Cachofeiro V., Rodríguez-Moyano M., Gomez A.M., Ordóñez A., Smani T. Urocortin induces positive inotropic effect in rat heart. Cardiovasc. Res. 2009, 83:717-725.
30. Wang Y., Chen Y., Chen M., Xu W. AKAPs competing peptide HT31 disrupts the inhibitory effect of PKA on RhoA activity. Oncol. Rep. 2006, 16:755-761.
31. Malbon C.C., Tao J., Shumay E., Wang H.Y. AKAP (A-kinase anchoring protein) domains: beads of structure-function on the necklace of G-protein signaling. Biochem. Soc. Trans. 2004, 32:861-864.
32. Chen M.H., Malbon C.C. G-protein-coupled receptor-associated A-kinase anchoring proteins AKAP5 and AKAP12: differential trafficking and distribution. Cell. Signal. 2009, 21:136-142.
33. Hupfeld C.J., Resnik J.L., Ugi S., Olefsky Insulin-induced J.M. beta-arrestin1 Ser-412 phosphorylation is a mechanism for desensitization of ERK activation by Galphai-coupled receptors. J. Biol. Chem. 2005, 280:1016-1023.
34. Graziani G., Tentori L., Portarena I., Barbarino M., Tringali G., Pozzoli G., Navarra P. CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 2002, 143:807-813.
35. Graziani G., Tentori L., Muzi A., Vergati M., Tringali G., Pozzoli G., Navarra Evidence P. that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol. Cell. Endocrinol. 2007, 264:44-49.
36. Cao J., Cetrulo C.L., Theoharides T.C. Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. Mol. Pharmacol. 2006, 69:998-1006.
37. Elliott-Hunt C.R., Kazlauskaite J., Wilde G.J.C., Grammatopoulos D., Hillhouse E.W. Potential signaling pathways underlying corticotropin-releasing hormone's mediated neuroprotectionfrom excitotoxicity in rat hippocampus. J. Neurochem. 2002, 80:416-425.
38. Fujita T., Meguro T., Fukuyama R., Nakamuta H., Koida M. New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. Checkpoint of modulation by cyclic AMP. J. Biol. Chem. 2002, 277:22191-22200.
39. Laroche-Joubert N., Marsy S., Michelet S., Imbert-Teboul M., Doucet A. Protein kinase A-independent activation of ERK and H,K-ATPase by cAMP in native kidney cells: role of Epac I. J. Biol. Chem. 2002, 277:18598-18604.
40. Hewer R.C., Sala-Newby G.B., Wu Y.J., Newby A.C., Bond M. PKA and Epac synergistically inhibit smooth muscle cell proliferation. J. Mol. Cell. Cardiol. 2011, 50:87-98.
41. Li J., O'Connor K.L., Cheng X., Mei F.C., Uchida T., Townsend C.M., Evers B.M. Cyclic adenosine 5'-monophosphate-stimulated neurotensin secretion is mediated through Rap1 downstream of both Epac and protein kinase A signaling pathways. Mol. Endocrinol. 2007, 21:159-171.
42. Leone V., di Palma A., Ricchi P., Acquaviva F., Giannouli M., Di Prisco A.M., Iuliano F., Acquaviva A.M. PGE2 inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K association and cAMP-dependent kinase A activation. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293:G673-G681.
43. Ciullo I., Diez-Roux G., Di Domenico M., Migliaccio A., Avvedimento E.V. cAMP signaling selectively influences Ras effectors pathways. Oncogene 2001, 20:1186-1192.
44. Wietfeld D., Heinrich N., Furkert J., Fechner K., Beyermann M., Bienert M., Berger H. Regulation of the coupling to different G proteins of rat corticotropin-releasing factor receptor type 1 in human embryonic kidney 293 cells. J. Biol. Chem. 2004, 279:38386-38394.
45. Brar B.K., Stephanou A., Knight R., Latchman D.S. Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J. Mol. Cell. Cardiol. 2002, 34:483-492.
46. Wang M.J., Lin S.Z., Kuo J.S., Huang H.Y., Tzeng S.F., Liao C.H., Chen D.C., Chen W.F. Urocortin modulates inflammatory response and neurotoxicity induced by microglial activation. J. Immunol. 2007, 179:6204-6214.
47. Valentim L., Laurence K.M., Townsend P.A., Carroll C.J., Soond S., Scarabelli T.M., Knight R.A., Latchman D.S., Stephanou A. Urocortin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury. J. Mol. Cell. Cardiol. 2006, 40:846-852.
48. Chanalaris A., Lawrence K.M., Townsend P.A., Davidson S., Jamshidi Y., Stephanou A., Knight R.D., Hsu S.Y., Hsueh A.J., Latchman D.S. Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. Biochem. Biophys. Res. Commun. 2005, 328:442-448.
49. Fan G.H., Yang W., Sai J., Richmond A. Phosphorylation-independent association of CXCR2 with the protein phosphatase 2A core enzyme. J. Biol. Chem. 2001, 276:16960-16968.
50. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.